Interpharma, the association of research-based pharmaceutical companies in Switzerland, believes that access to innovative medicines is worsening since the US introduced policies to lower drug prices in line with peer countries. A survey of member companies has shown that pharmaceutical manufacturers no longer consider themselves able, under the current framework, to launch new therapies in Switzerland in a timely manner without jeopardising prices in the US, Interpharma announced on Thursday. Between January 2025 and June 2026, Interpharma’s members had not submitted seven out of a total of 22 new innovative medicines for inclusion on the Specialities List, which is the list of medicines reimbursed by insurance. In the case of three others, they had even decided not to submit them to the Swiss medicines agency Swissmedic for authorisation. + Drugmakers reassess Europe as Trump overhauls drug-pricing rules According to Interpharma, this underscores the US administration’s policy ...
Full story here
Are you the author?
Previous post
See more for
Next post
Tags: Featured,newsletter
Home › 3) Swiss Markets and News › 3.) Swissinfo Business and Economy › Swiss pharma group warns access to new medicine is worsening
Previous post
Next post
Swiss pharma group warns access to new medicine is worsening
Published on August 13, 2026
Permanent link to this article: https://snbchf.com/2026/08/swiss-pharma-warns-access-new-medicine-worsening/
Receive a Daily Mail from this Blog
Live Currency Cross Rates
On Swiss National Bank
-
SNB Sight Deposits: is stable 0.0 billion francs compared to the previous week
2026-07-28 -
Household wealth in 2025
2026-04-28 -
Heads up for NZD and CHF traders, RBNZ Gov Breman and SNB Chair Schlegel to speak
2026-04-15 -
Swiss franc appreciation has led to tighter monetary conditions – SNB minutes
2026-04-16 -
SNB’s Chairman Schlegel: A few months of negative inflation wouldn’t be a problem
2026-01-21
Main SNB Background Info
-
SNB Sight Deposits: is stable 0.0 billion francs compared to the previous week
2026-07-28 -
The Secret History Of The Banking Crisis
2017-08-14 -
SNB Balance Sheet Now Over 100 percent GDP
2016-08-29 -
The relationship between CHF and gold
2016-07-23 -
CHF Price Movements: Correlations between CHF and the German Economy
2016-07-22
Featured and recent
-
US Debt Trap: A Crisis Without A Calendar -
Crisis Will Test Our Mettle – Lessons From 9/11 -
Swiss firms fear exclusion from EU innovation procurement -
Swiss trade union calls for 2.5% pay raise -
US Dollar Bid Ahead of ECB Rate Hike -
Swiss firms ‘in line for $2bn US tariff refunds’ -
China’s high-tech rise puts competitive pressure on Switzerland -
Bessent Threatens ‘I Am The House’: Bond Traders Should Listen -
US medical device company to cut 580 jobs in Switzerland -
Swiss fragrance firm Givaudan plans expansion in Morocco
More from this category
US Debt Trap: A Crisis Without A Calendar11 Sep 2026
Crisis Will Test Our Mettle – Lessons From 9/1111 Sep 2026
Swiss firms fear exclusion from EU innovation procurement10 Sep 2026
Swiss trade union calls for 2.5% pay raise10 Sep 2026
US Dollar Bid Ahead of ECB Rate Hike10 Sep 2026
Swiss firms ‘in line for $2bn US tariff refunds’10 Sep 2026
China’s high-tech rise puts competitive pressure on Switzerland10 Sep 2026
Bessent Threatens ‘I Am The House’: Bond Traders Should Listen10 Sep 2026
US medical device company to cut 580 jobs in Switzerland10 Sep 2026
Swiss fragrance firm Givaudan plans expansion in Morocco10 Sep 2026
Swiss pharma firm Lonza to build new factory in US10 Sep 2026
Switzerland bans purchase and import of Sudanese gold10 Sep 2026
Small Swiss firms asked to help expand wind power9 Sep 2026
Oil Higher, Yen Consolidates, US to Reveal Bond Buyback Plans9 Sep 2026
Is Warsh Setting Up A Policy Error?9 Sep 2026
Geneva vs Zurich: which is the better safe haven?9 Sep 2026
Hike Or Hold? Debating The Coming Fed Decision9 Sep 2026
Swiss oddities8 Sep 2026
Why Switzerland has such low interest rates8 Sep 2026
The week in Switzerland8 Sep 2026












